Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: Lessons learned from animal models and human genetics

Frontiers in Immunology

Volumn 4, Issue SEP, 2013, Pages

  Pastorelli, Luca ^a,b,c   Salvo, Carlo De ^a,c   Mercado, Joseph R ^a   Vecchi, Maurizio ^b,c   Pizarro, Theresa T ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

Animal models of intestinal inflammation; Crohn's disease; Gut immune homeostasis; Inflammatory bowel disease genetics; Innate immunity; Intestinal barrier function; Intestinal epithelial cells; Ulcerative colitis

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 23; INTERLEUKIN 8; NERVE CELL ADHESION MOLECULE; NUCLEAR FACTOR KAPPA B SUBUNIT 1; PATTERN RECOGNITION RECEPTOR; PEPTIDES AND PROTEINS; PROBIOTIC AGENT; PROTEIN P120; PROTEIN ZO1; PROTEIN ZO2; PROTEIN ZO3; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TREFOIL FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CELL ADHESION; CELL HYPERPLASIA; CELL PROLIFERATION; CELLULAR STRESS RESPONSE; CROHN DISEASE; ENTERITIS; GENE EXPRESSION; HUMAN; HUMAN GENETICS; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTESTINE EPITHELIUM; NONHUMAN; PERMEABILITY BARRIER; PROTEIN EXPRESSION; PROTEIN LOSING GASTROENTEROPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; STOMACH MUCUS;

EID: 84886014303     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00280     Document Type: Review

References (202)

1. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med (2000) 343:338-44. doi:10.1056/NEJM200008033430506.
2. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol (2004) 4:499-511. doi:10.1038/nri1391.
3. Gay NJ, Keith FJ. Drosophila toll IL-1 receptor. Nature (1991) 351:355-6. doi:10.1038/351355b0.
4. Belvin MP, Anderson KV. A conserved signaling pathway: the Drosophila toll-dorsal pathway. Annu Rev Cell Dev Biol (1996) 12:393-416. doi:10.1146/annurev.cellbio.12.1.393.
5. Vijay-Kumar M, Sanders CJ, Taylor RT, Kumar A, Aitken JD, Sitaraman SV, et al. Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest (2007) 117:3909-21.
6. Carvalho FA, Nalbantoglu I, Ortega-Fernandez S, Aitken JD, Su Y, Koren O, et al. Interleukin-1beta (IL-1beta) promotes susceptibility of toll-like receptor 5 (TLR5) deficient mice to colitis. Gut (2012) 61:373-84. doi:10.1136/gut.2011.240556.
7. Sundberg JP, Elson CO, Bedigian H, Birkenmeier EH. Spontaneous, heritable colitis in a new substrain of C3H/HeJ mice. Gastroenterology (1994) 107:1726-35.
8. Beckwith J, Cong Y, Sundberg JP, Elson CO, Leiter EH. Cdcs1, a major colitogenic locus in mice, regulates innate and adaptive immune response to enteric bacterial antigens. Gastroenterology (2005) 129:1473-84. doi:10.1053/j.gastro.2005.07.057.
9. Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest (2004) 113:1296-306.
10. Farmer MA, Sundberg JP, Bristol IJ, Churchill GA, Li R, Elson CO, et al. A major quantitative trait locus on chromosome 3 controls colitis severity in IL-10-deficient mice. Proc Natl Acad Sci U S A (2001) 98:13820-5. doi:10.1073/pnas.241258698.
11. Carvalho FA, Barnich N, Sauvanet P, Darcha C, Gelot A, Darfeuille-Michaud A. Crohn's disease-associated Escherichia coli LF82 aggravates colitis in injured mouse colon via signaling by flagellin. Inflamm Bowel Dis (2008) 14:1051-60. doi:10.1002/ibd.20423.
12. Boudeau J, Glasser AL, Masseret E, Joly B, Darfeuille-Michaud A. Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease. Infect Immun (1999) 67:4499-509.
13. Abraham C, Cho JH. Bugging of the intestinal mucosa. N Engl J Med (2007) 357:708-10. doi:10.1056/NEJMcibr073420.
14. Gewirtz AT, Vijay-Kumar M, Brant SR, Duerr RH, Nicolae DL, Cho JH. Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am J Physiol Gastrointest Liver Physiol (2006) 290:G1157-63. doi:10.1152/ajpgi.00544.2005.
15. Fukata M, Michelsen KS, Eri R, Thomas LS, Hu B, Lukasek K, et al. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 288:G1055-65. doi:10.1152/ajpgi.00328.2004.
16. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun (2000) 68:7010-7. doi:10.1128/IAI.68.12.7010-7017.2000.
17. Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot T, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut (2004) 53:987-92. doi:10.1136/gut.2003.030205.
18. Pierik M, Joossens S, van Steen K, Van Schuerbeek N, Vlietinck R, Rutgeerts P, et al. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis (2006) 12:1-8. doi:10.1097/01.MIB.0000195389.11645.ab.
19. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology (2007) 132:1359-74. doi:10.1053/j.gastro.2007.02.056.
20. Podolsky DK, Gerken G, Eyking A, Cario E. Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. Gastroenterology (2009) 137:209-20. doi:10.1053/j.gastro.2009.03.007.
21. Pedersen G, Andresen L, Matthiessen MW, Rask-Madsen J, Brynskov J. Expression of toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium. Clin Exp Immunol (2005) 141:298-306. doi:10.1111/j.1365-2249.2005.02848.x.
22. Torok HP, Glas J, Tonenchi L, Bruennler G, Folwaczny M, Folwaczny C. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology (2004) 127:365-6. doi:10.1053/j.gastro.2004.05.051.
23. Nenci A, Becker C, Wullaert A, Gareus R, van Loo G, Danese S, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature (2007) 446:557-61. doi:10.1038/nature05698.
24. Kajino-Sakamoto R, Inagaki M, Lippert E, Akira S, Robine S, Matsumoto K, et al. Enterocyte-derived TAK1 signaling prevents epithelium apoptosis and the development of ileitis and colitis. J Immunol (2008) 181:1143-52.
25. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 411:599-603. doi:10.1038/35079107.
26. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature (2001) 411:603-6. doi:10.1038/35079114.
27. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem (2001) 276:4812-8. doi:10.1074/jbc. M008072200.
28. Ogura Y, Lala S, Xin W, Smith E, Dowds TA, Chen FF, et al. Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut (2003) 52:1591-7. doi:10.1136/gut.52.11.1591.
29. Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem (2003) 278:5509-12. doi:10.1074/jbc. C200673200.
30. Schreiber S, Rosenstiel P, Albrecht M, Hampe J, Krawczak M. Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet (2005) 6:376-88. doi:10.1038/nrg1607.
31. Abbott DW, Wilkins A, Asara JM, Cantley LC. The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr Biol (2004) 14:2217-27. doi:10.1016/j.cub.2004.12.032.
32. Lala S, Ogura Y, Osborne C, Hor SY, Bromfield A, Davies S, et al. Crohn's disease and the NOD2 gene: a role for Paneth cells. Gastroenterology (2003) 125:47-57. doi:10.1016/S0016-5085(03)00661-9.
33. Wehkamp J, Schmid M, Fellermann K, Stange EF. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol (2005) 77:460-5. doi:10.1189/jlb.0904543.
34. Van Limbergen J, Russell RK, Nimmo ER, Ho GT, Arnott ID, Wilson DC, et al. Genetics of the innate immune response in inflammatory bowel disease. Inflamm Bowel Dis (2007) 13:338-55. doi:10.1002/ibd.20096.
35. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol (2003) 3:710-20. doi:10.1038/nri1180.
36. Koslowski MJ, Kubler I, Chamaillard M, Schaeffeler E, Reinisch W, Wang G, et al. Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS One (2009) 4:e4496. doi:10.1371/journal.pone.0004496.
37. Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut (2004) 53:1658-64. doi:10.1136/gut.2003.032805.
38. Voss E, Wehkamp J, Wehkamp K, Stange EF, Schroder JM, Harder J. NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem (2006) 281:2005-11. doi:10.1074/jbc. M511044200.
39. Takahashi N, Vanlaere I, de Rycke R, Cauwels A, Joosten LA, Lubberts E, et al. IL-17 produced by Paneth cells drives TNF-induced shock. J Exp Med (2008) 205:1755-61. doi:10.1084/jem.20080588.
40. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol (2005) 6:1123-32. doi:10.1038/ni1254.
41. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 201:233-40. doi:10.1084/jem.20041257.
42. Hirota K, Hashimoto M, Yoshitomi H, Tanaka S, Nomura T, Yamaguchi T, et al. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med (2007) 204:41-7. doi:10.1084/jem.20062259.
43. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut (2003) 52:65-70. doi:10.1136/gut.52.1.65.
44. Buhner S, Buning C, Genschel J, Kling K, Herrmann D, Dignass A, et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut (2006) 55:342-7. doi:10.1136/gut.2005.065557.
45. D'Inca R, Annese V, di Leo V, Latiano A, Quaino V, Abazia C, et al. Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease. Aliment Pharmacol Ther (2006) 23:1455-61. doi:10.1111/j.1365-2036.2006.02916.x.
46. Schreiber S. Slipping the barrier: how variants in CARD15 could alter permeability of the intestinal wall and population health. Gut (2006) 55:308-9. doi:10.1136/gut.2005.076075.
47. Chamaillard M, Hashimoto M, Horie Y, Masumoto J, Qiu S, Saab L, et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol (2003) 4:702-7. doi:10.1038/ni945.
48. McGovern DP, Hysi P, Ahmad T, van Heel DA, Moffatt MF, Carey A, et al. Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet (2005) 14:1245-50. doi:10.1093/hmg/ddi135.
49. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet (2007) 39:596-604. doi:10.1038/ng2032.
50. Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet (2007) 39:830-2. doi:10.1038/ng2061.
51. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science (2000) 290:1717-21. doi:10.1126/science.290.5497.1717.
52. Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 39:1329-37. doi:10.1038/ng.2007.17.
53. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet (2007) 39:207-11. doi:10.1038/ng1954.
54. Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature (2008) 456:259-63. doi:10.1038/nature07416.
55. Shorter RG, Huizenga KA, Spencer RJ. A working hypothesis for the etiology and pathogenesis of nonspecific inflammatory bowel disease. Am J Dig Dis (1972) 17:1024-32. doi:10.1007/BF02239143.
56. Cereijido M, Contreras RG, Flores-Benitez D, Flores-Maldonado C, Larre I, Ruiz A, et al. New diseases derived or associated with the tight junction. Arch Med Res (2007) 38:465-78. doi:10.1016/j.arcmed.2007.02.003.
57. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology (1990) 98:694-702.
58. Poritz LS, Garver KI, Green C, Fitzpatrick L, Ruggiero F, Koltun WA. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J Surg Res (2007) 140:12-9. doi:10.1016/j.jss.2006.07.050.
59. Mahler M, Bristol IJ, Sundberg JP, Churchill GA, Birkenmeier EH, Elson CO, et al. Genetic analysis of susceptibility to dextran sulfate sodium-induced colitis in mice. Genomics (1999) 55:147-56. doi:10.1006/geno.1998.5636.
60. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology (1994) 107:1643-52.
61. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology (1989) 96:795-803.
62. Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science (1995) 270:1203-7. doi:10.1126/science.270.5239.1203.
63. Smalley-Freed WG, Efimov A, Burnett PE, Short SP, Davis MA, Gumucio DL, et al. p120-Catenin is essential for maintenance of barrier function and intestinal homeostasis in mice. J Clin Invest (2010) 120:1824-35. doi:10.1172/JCI41414.
64. Rudolph U, Finegold MJ, Rich SS, Harriman GR, Srinivasan Y, Brabet P, et al. Gi2 alpha protein deficiency: a model of inflammatory bowel disease. J Clin Immunol (1995) 15:101S-5S. doi:10.1007/BF01540899.
65. Saha C, Nigam SK, Denker BM. Involvement of Galphai2 in the maintenance and biogenesis of epithelial cell tight junctions. J Biol Chem (1998) 273:21629-33. doi:10.1074/jbc.273.34.21629.
66. Laukoetter MG, Nava P, Lee WY, Severson EA, Capaldo CT, Babbin BA, et al. JAM-A regulates permeability and inflammation in the intestine in vivo. J Exp Med (2007) 204:3067-76. doi:10.1084/jem.20071416.
67. Woodfin A, Reichel CA, Khandoga A, Corada M, Voisin MB, Scheiermann C, et al. JAM-A mediates neutrophil transmigration in a stimulus-specific manner in vivo: evidence for sequential roles for JAM-A and PECAM-1 in neutrophil transmigration. Blood (2007) 110:1848-56. doi:10.1182/blood-2006-09-047431.
68. Cera MR, Del Prete A, Vecchi A, Corada M, Martin-Padura I, Motoike T, et al. Increased DC trafficking to lymph nodes and contact hypersensitivity in junctional adhesion molecule-A-deficient mice. J Clin Invest (2004) 114:729-38. doi:10.1172/JCI200421231.
69. Vetrano S, Rescigno M, Rosaria Cera M, Correale C, Rumio C, Doni A, et al. Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology (2008) 135:173-84. doi:10.1053/j.gastro.2008.04.002.
70. Khounlotham M, Kim W, Peatman E, Nava P, Medina-Contreras O, Addis C, et al. Compromised intestinal epithelial barrier induces adaptive immune compensation that protects from colitis. Immunity (2012) 37:563-73. doi:10.1016/j.immuni.2012.06.017.
71. Schulzke JD, Gitter AH, Mankertz J, Spiegel S, Seidler U, Amasheh S, et al. Epithelial transport and barrier function in occludin-deficient mice. Biochim Biophys Acta (2005) 1669:34-42. doi:10.1016/j.bbamem.2005.01.008.
72. Tamura A, Kitano Y, Hata M, Katsuno T, Moriwaki K, Sasaki H, et al. Megaintestine in claudin-15-deficient mice. Gastroenterology (2008) 134:523-34. doi:10.1053/j.gastro.2007.11.040.
73. Su L, Shen L, Clayburgh DR, Nalle SC, Sullivan EA, Meddings JB, et al. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology (2009) 136:551-63. doi:10.1053/j.gastro.2008.10.081.
74. Kosiewicz MM, Nast CC, Krishnan A, Rivera-Nieves J, Moskaluk CA, Matsumoto S, et al. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J Clin Invest (2001) 107:695-702. doi:10.1172/JCI10956.
75. Pizarro TT, Pastorelli L, Bamias G, Garg RR, Reuter BK, Mercado JR, et al. SAMP1/YitFc mouse strain: a spontaneous model of Crohn's disease-like ileitis. Inflamm Bowel Dis (2011) 17:2566-84. doi:10.1002/ibd.21638.
76. Rivera-Nieves J, Bamias G, Vidrich A, Marini M, Pizarro TT, McDuffie MJ, et al. Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis. Gastroenterology (2003) 124:972-82. doi:10.1053/gast.2003.50148.
77. Vidrich A, Buzan JM, Barnes S, Reuter BK, Skaar K, Ilo C, et al. Altered epithelial cell lineage allocation and global expansion of the crypt epithelial stem cell population are associated with ileitis in SAMP1/YitFc mice. Am J Pathol (2005) 166:1055-67. doi:10.1016/S0002-9440(10)62326-7.
78. Olson TS, Reuter BK, Scott KG, Morris MA, Wang XM, Hancock LN, et al. The primary defect in experimental ileitis originates from a nonhematopoietic source. J Exp Med (2006) 203:541-52. doi:10.1084/jem.20050407.
79. Furuse M, Furuse K, Sasaki H, Tsukita S. Conversion of zonulae occludentes from tight to leaky strand type by introducing claudin-2 into Madin-Darby canine kidney I cells. J Cell Biol (2001) 153:263-72. doi:10.1083/jcb.153.2.263.
80. Kozaiwa K, Sugawara K, Smith MF Jr, Carl V, Yamschikov V, Belyea B, et al. Identification of a quantitative trait locus for ileitis in a spontaneous mouse model of Crohn's disease: SAMP1/YitFc. Gastroenterology (2003) 125:477-90. doi:10.1016/S0016-5085(03)00876-X.
81. Reuter BK, Pizarro TT. Mechanisms of tight junction dysregulation in the SAMP1/YitFc model of Crohn's disease-like ileitis. Ann N Y Acad Sci (2009) 1165:301-7. doi:10.1111/j.1749-6632.2009.04035.x.
82. Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, Rotter JI. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med (1986) 105:883-5. doi:10.7326/0003-4819-105-6-883.
83. Kucharzik T, Walsh SV, Chen J, Parkos CA, Nusrat A. Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am J Pathol (2001) 159:2001-9. doi:10.1016/S0002-9440(10)63051-9.
84. D'Inca R, Di Leo V, Corrao G, Martines D, D'Odorico A, Mestriner C, et al. Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol (1999) 94:2956-60. doi:10.1111/j.1572-0241.1999.01444.x.
85. Arnott ID, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol (2000) 35:1163-9. doi:10.1080/003655200750056637.
86. Prasad S, Mingrino R, Kaukinen K, Hayes KL, Powell RM, Macdonald TT, et al. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest (2005) 85:1139-62. doi:10.1038/labinvest.3700316.
87. Zeissig S, Burgel N, Gunzel D, Richter J, Mankertz J, Wahnschaffe U, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut (2007) 56:61-72. doi:10.1136/gut.2006.094375.
88. Ridyard AE, Brown JK, Rhind SM, Else RW, Simpson JW, Miller HR. Apical junction complex protein expression in the canine colon: differential expression of claudin-2 in the colonic mucosa in dogs with idiopathic colitis. J Histochem Cytochem (2007) 55:1049-58. doi:10.1369/jhc.7A7211.2007.
89. Barrett JC, Lee JC, Lees CW, Prescott NJ, Anderson CA, Phillips A, et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet (2009) 41:1330-4. doi:10.1038/ng.483.
90. Battle MA, Konopka G, Parviz F, Gaggl AL, Yang C, Sladek FM, et al. Hepatocyte nuclear factor 4alpha orchestrates expression of cell adhesion proteins during the epithelial transformation of the developing liver. Proc Natl Acad Sci U S A (2006) 103:8419-24. doi:10.1073/pnas.0600246103.
91. Garrison WD, Battle MA, Yang C, Kaestner KH, Sladek FM, Duncan SA. Hepatocyte nuclear factor 4alpha is essential for embryonic development of the mouse colon. Gastroenterology (2006) 130:1207-20. doi:10.1053/j.gastro.2006.01.003.
92. Ahn SH, Shah YM, Inoue J, Morimura K, Kim I, Yim S, et al. Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm Bowel Dis (2008) 14:908-20. doi:10.1002/ibd.20413.
93. van Bodegraven AA, Curley CR, Hunt KA, Monsuur AJ, Linskens RK, Onnie CM, et al. Genetic variation in myosin IXB is associated with ulcerative colitis. Gastroenterology (2006) 131:1768-74. doi:10.1053/j.gastro.2006.09.011.
94. McGovern DP, Taylor KD, Landers C, Derkowski C, Dutridge D, Dubinsky M, et al. MAGI2 genetic variation and inflammatory bowel disease. Inflamm Bowel Dis (2008) 15(1):75-83. doi:10.1002/ibd.20611.
95. Wapenaar MC, Monsuur AJ, van Bodegraven AA, Weersma RK, Bevova MR, Linskens RK, et al. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis. Gut (2008) 57:463-7. doi:10.1136/gut.2007.133132.
96. Post PL, Tyska MJ, O'Connell CB, Johung K, Hayward A, Mooseker MS. Myosin-IXb is a single-headed and processive motor. J Biol Chem (2002) 277:11679-83. doi:10.1074/jbc. M111173200.
97. Monsuur AJ, de Bakker PI, Alizadeh BZ, Zhernakova A, Bevova MR, Strengman E, et al. Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat Genet (2005) 37:1341-4. doi:10.1038/ng1680.
98. Takahashi D, Hase K, Kimura S, Nakatsu F, Ohmae M, Mandai Y, et al. The epithelia-specific membrane trafficking factor AP-1B controls gut immune homeostasis in mice. Gastroenterology (2011) 141:621-32. doi:10.1053/j.gastro.2011.04.056.
99. Obata Y, Takahashi D, Ebisawa M, Kakiguchi K, Yonemura S, Jinnohara T, et al. Epithelial cell-intrinsic Notch signaling plays an essential role in the maintenance of gut immune homeostasis. J Immunol (2012) 188:2427-36. doi:10.4049/jimmunol.1101128.
100. Kaser A, Lee AH, Franke A, Glickman JN, Zeissig S, Tilg H, et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell (2008) 134:743-56. doi:10.1016/j.cell.2008.07.021.
101. Garabedian EM, Roberts LJ, McNevin MS, Gordon JI. Examining the role of Paneth cells in the small intestine by lineage ablation in transgenic mice. J Biol Chem (1997) 272:23729-40. doi:10.1074/jbc.272.38.23729.
102. Van Limbergen J, Russell RK, Nimmo ER, Satsangi J. The genetics of inflammatory bowel disease. Am J Gastroenterol (2007) 102:2820-31. doi:10.1111/j.1572-0241.2007.01527.x.
103. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol (1998) 161:5733-44.
104. Resta-Lenert S, Smitham J, Barrett KE. Epithelial dysfunction associated with the development of colitis in conventionally housed mdr1a-/-mice. Am J Physiol Gastrointest Liver Physiol (2005) 289:G153-62. doi:10.1152/ajpgi.00395.2004.
105. Staley EM, Schoeb TR, Lorenz RG. Differential susceptibility of P-glycoprotein deficient mice to colitis induction by environmental insults. Inflamm Bowel Dis (2009) 15:684-96. doi:10.1002/ibd.20824.
106. Collett A, Higgs NB, Gironella M, Zeef LA, Hayes A, Salmo E, et al. Early molecular and functional changes in colonic epithelium that precede increased gut permeability during colitis development in mdr1a(-/-) mice. Inflamm Bowel Dis (2008) 14(5):620-31. doi:10.1002/ibd.20375.
107. Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet (2003) 73:1282-92. doi:10.1086/379927.
108. Tamai I, Ohashi R, Nezu JI, Sai Y, Kobayashi D, Oku A, et al. Molecular and functional characterization of organic cation/carnitine transporter family in mice. J Biol Chem (2000) 275:40064-72. doi:10.1074/jbc. M005340200.
109. Peltekova VD, Wintle RF, Rubin LA, Amos CI, Huang Q, Gu X, et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet (2004) 36:471-5. doi:10.1038/ng1339.
110. Stoll M, Corneliussen B, Costello CM, Waetzig GH, Mellgard B, Koch WA, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet (2004) 36:476-80. doi:10.1038/ng1345.
111. Nakamura H, Sudo T, Tsuiki H, Miyake H, Morisaki T, Sasaki J, et al. Identification of a novel human homolog of the Drosophila dlg, P-dlg, specifically expressed in the gland tissues and interacting with p55. FEBS Lett (1998) 433:63-7. doi:10.1016/S0014-5793(98)00882-5.
112. Festen EA, Zhernakova A, Wijmenga C, Weersma RK. Association of DLG5 variants with gluten-sensitive enteropathy. Gut (2008) 57:1027-8. doi:10.1136/gut.2007.144857.
113. Friedrichs F, Henckaerts L, Vermeire S, Kucharzik T, Seehafer T, Moller-Krull M, et al. The Crohn's disease susceptibility gene DLG5 as a member of the CARD interaction network. J Mol Med (2008) 86:423-32. doi:10.1007/s00109-008-0307-5.
114. Biank V, Friedrichs F, Babusukumar U, Wang T, Stoll M, Broeckel U, et al. DLG5 R30Q variant is a female-specific protective factor in pediatric onset Crohn's disease. Am J Gastroenterol (2007) 102:391-8. doi:10.1111/j.1572-0241.2006.01011.x.
115. Browning BL, Annese V, Barclay ML, Bingham SA, Brand S, Buning C, et al. Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts. J Med Genet (2008) 45:36-42. doi:10.1136/jmg.2007.050773.
116. Gibson P, Rosella O, Nov R, Young G. Colonic epithelium is diffusely abnormal in ulcerative colitis and colorectal cancer. Gut (1995) 36:857-63. doi:10.1136/gut.36.6.857.
117. Brandtzaeg P. Molecular and cellular aspects of the secretory immunoglobulin system. APMIS (1995) 103:1-19. doi:10.1111/j.1699-0463.1995.tb01073.x.
118. Weinberg ED. Human lactoferrin: a novel therapeutic with broad spectrum potential. J Pharm Pharmacol (2001) 53:1303-10. doi:10.1211/0022357011777792.
119. Proud D, Kaplan AP. Kinin formation: mechanisms and role in inflammatory disorders. Annu Rev Immunol (1988) 6:49-83. doi:10.1146/annurev.iy.06.040188.000405.
120. Chao J, Schmaier A, Chen LM, Yang Z, Chao L. Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. J Lab Clin Med (1996) 127:612-20. doi:10.1016/S0022-2143(96)90152-3.
121. Devani M, Cugno M, Vecchi M, Ferrero S, Di Berardino F, Avesani EC, et al. Kallikrein-kinin system activation in Crohn's disease: differences in intestinal and systemic markers. Am J Gastroenterol (2002) 97:2026-32. doi:10.1111/j.1572-0241.2002.05919.x.
122. Devani M, Vecchi M, Ferrero S, Avesani EC, Arizzi C, Chao L, et al. Kallikrein-kinin system in inflammatory bowel diseases: intestinal involvement and correlation with the degree of tissue inflammation. Dig Liver Dis (2005) 37:665-73. doi:10.1016/j.dld.2005.01.021.
123. Van der Sluis M, De Koning BA, De Bruijn AC, Velcich A, Meijerink JP, Van Goudoever JB, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology (2006) 131:117-29. doi:10.1053/j.gastro.2006.04.020.
124. Heazlewood CK, Cook MC, Eri R, Price GR, Tauro SB, Taupin D, et al. Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med (2008) 5:e54. doi:10.1371/journal.pmed.0050054.
125. Einerhand AW, Renes IB, Makkink MK, van der Sluis M, Buller HA, Dekker J. Role of mucins in inflammatory bowel disease: important lessons from experimental models. Eur J Gastroenterol Hepatol (2002) 14:757-65. doi:10.1097/00042737-200207000-00008.
126. Kyo K, Parkes M, Takei Y, Nishimori H, Vyas P, Satsangi J, et al. Association of ulcerative colitis with rare VNTR alleles of the human intestinal mucin gene, MUC3. Hum Mol Genet (1999) 8:307-11. doi:10.1093/hmg/8.2.307.
127. Kyo K, Muto T, Nagawa H, Lathrop GM, Nakamura Y. Associations of distinct variants of the intestinal mucin gene MUC3A with ulcerative colitis and Crohn's disease. J Hum Genet (2001) 46:5-20. doi:10.1007/s100380170118.
128. Guilmeau S, Flandez M, Bancroft L, Sellers RS, Tear B, Stanley P, et al. Intestinal deletion of Pofut1 in the mouse inactivates notch signaling and causes enterocolitis. Gastroenterology (2008) 135:e1-6. doi:10.1053/j.gastro.2008.05.050.
129. Bresso F, Askling J, Astegiano M, Demarchi B, Sapone N, Rizzetto M, et al. Potential role for the common cystic fibrosis DeltaF508 mutation in Crohn's disease. Inflamm Bowel Dis (2007) 13:531-6. doi:10.1002/ibd.20067.
130. Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ. Sargramostim for active Crohn's disease. N Engl J Med (2005) 352:2193-201. doi:10.1056/NEJMoa041109.
131. Unal AE, Cevikel MH, Ozgun H, Tunger A. Effect of granulocyte-macrophage colony stimulating factor on bacterial translocation after experimental obstructive jaundice. Eur J Surg (2001) 167:366-70. doi:10.1080/110241501750215267.
132. Kurt-Jones EA, Mandell L, Whitney C, Padgett A, Gosselin K, Newburger PE, et al. Role of toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils. Blood (2002) 100:1860-8.
133. Armitage JO. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood (1998) 92:4491-508.
134. Ramsay RG, Micallef SJ, Williams B, Lightowler S, Vincan E, Heath JK, et al. Colony-stimulating factor-1 promotes clonogenic growth of normal murine colonic crypt epithelial cells in vitro. J Interferon Cytokine Res (2004) 24:416-27. doi:10.1089/1079990041535638.
135. Pagnini C, Cominelli F. Probiotics in experimental and human inflammatory bowel disease: discussion points. Dig Liver Dis (2006) 38(Suppl 2):S270-3. doi:10.1016/S1590-8658(07)60008-5.
136. Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis (2008) 14(11):1585-96. doi:10.1002/ibd.20525.
137. Dogi CA, Galdeano CM, Perdigon G. Gut immune stimulation by non pathogenic Gram(+) and Gram(-) bacteria. Comparison with a probiotic strain. Cytokine (2008) 41:223-31. doi:10.1016/j.cyto.2007.11.014.
138. Wehkamp J, Harder J, Wehkamp K, Wehkamp-von Meissner B, Schlee M, Enders C, et al. NF-kappaB-and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun (2004) 72:5750-8. doi:10.1128/IAI.72.10.5750-5758.2004.
139. Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2-and toll-like receptor 4-dependent pathways. Infect Immun (2006) 74:4075-82. doi:10.1128/IAI.01449-05.
140. Bai AP, Ouyang Q. Probiotics and inflammatory bowel diseases. Postgrad Med J (2006) 82:376-82. doi:10.1136/pgmj.2005.040899.
141. Bernet MF, Brassart D, Neeser JR, Servin AL. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut (1994) 35:483-9. doi:10.1136/gut.35.4.483.
142. Schultz M, Scholmerich J, Rath HC. Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases. Dig Dis (2003) 21:105-28. doi:10.1159/000073243.
143. Paterson BM, Lammers KM, Arrieta MC, Fasano A, Meddings JB. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther (2007) 26:757-66. doi:10.1111/j.1365-2036.2007.03413.x.
144. Arrieta MC, Madsen K, Doyle J, Meddings J. Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse. Gut (2009) 58:41-8. doi:10.1136/gut.2008.150888.
145. Leffler DA, Kelly CP, Abdallah HZ, Colatrella AM, Harris LA, Leon F, et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol (2012) 107:1554-62. doi:10.1038/ajg.2012.211.
146. Kong J, Zhang Z, Musch MW, Ning G, Sun J, Hart J, et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol (2008) 294:G208-16. doi:10.1152/ajpgi.00398.2007.
147. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol (2001) 154:369-87. doi:10.1083/jcb.200102028.
148. Simmons JD, Mullighan C, Welsh KI, Jewell DP. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut (2000) 47:211-4. doi:10.1136/gut.47.2.211.
149. Dresner-Pollak R, Ackerman Z, Eliakim R, Karban A, Chowers Y, Fidder HH. The BsmI vitamin D receptor gene polymorphism is associated with ulcerative colitis in Jewish Ashkenazi patients. Genet Test (2004) 8:417-20. doi:10.1089/gte.2004.8.417.
150. Whitacre CC, Reingold SC, O'Looney PA. A gender gap in autoimmunity. Science (1999) 283:1277-8. doi:10.1126/science.283.5406.1277.
151. Saibeni S, Cortinovis I, Beretta L, Tatarella M, Ferraris L, Rondonotti E, et al. Gender and disease activity influence health-related quality of life in inflammatory bowel diseases. Hepatogastroenterology (2005) 52:509-15.
152. Pelissier MA, Muller C, Hill M, Morfin R. Protection against dextran sodium sulfate-induced colitis by dehydroepiandrosterone and 7alpha-hydroxy-dehydroepiandrosterone in the rat. Steroids (2006) 71:240-8. doi:10.1016/j.steroids.2005.10.009.
153. Harnish DC, Albert LM, Leathurby Y, Eckert AM, Ciarletta A, Kasaian M, et al. Beneficial effects of estrogen treatment in the HLA-B27 transgenic rat model of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol (2004) 286:G118-25. doi:10.1152/ajpgi.00024.2003.
154. Braniste V, Leveque M, Buisson-Brenac C, Bueno L, Fioramonti J, Houdeau E. Oestradiol decreases colonic permeability through oestrogen receptor beta-mediated up-regulation of occludin and junctional adhesion molecule-A in epithelial cells. J Physiol (2009) 587:3317-28. doi:10.1113/jphysiol.2009.169300.
155. Shen J, Ran ZH, Tong JL, Xiao SD. Meta-analysis: the utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol Ther (2007) 26:653-63. doi:10.1111/j.1365-2036.2007.03418.x.
156. Celasco G, Moro L, Bozzella R, Mangano K, Quattrocchi C, Aiello C, et al. Efficacy of intracolonic administration of low-molecular-weight heparin CB-01-05, compared to other low-molecular-weight heparins and unfractionated heparin, in experimentally induced colitis in rat. Dig Dis Sci (2008) 53(12):3170-5. doi:10.1007/s10620-008-0299-6.
157. Pellequer Y, Meissner Y, Ubrich N, Lamprecht A. Epithelial heparin delivery via microspheres mitigates experimental colitis in mice. J Pharmacol Exp Ther (2007) 321:726-33. doi:10.1124/jpet.106.117226.
158. Pastorelli L, Saibeni S, Spina L, Signorelli C, Celasco G, de Franchis R, et al. Oral, colonic-release low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis. Aliment Pharmacol Ther (2008) 28:581-8. doi:10.1111/j.1365-2036.2008.03757.x.
159. Celasco G, Papa A, Jones R, Moro L, Bozzella R, Surace MM, et al. Clinical trial: oral colon-release parnaparin sodium tablets (CB-01-05 MMX) for active left-sided ulcerative colitis. Aliment Pharmacol Ther (2010) 31:375-86. doi:10.1111/j.1365-2036.2009.04194.x.
160. Murch SH, Macdonald TT, Walker-Smith JA, Levin M, Lionetti P, Klein NJ. Disruption of sulphated glycosaminoglycans in intestinal inflammation. Lancet (1993) 341:711-4. doi:10.1016/0140-6736(93)90485-Y.
161. Murch SH, Winyard PJ, Koletzko S, Wehner B, Cheema HA, Risdon RA, et al. Congenital enterocyte heparan sulphate deficiency with massive albumin loss, secretory diarrhoea, and malnutrition. Lancet (1996) 347:1299-301. doi:10.1016/S0140-6736(96)90941-1.
162. Westphal V, Murch S, Kim S, Srikrishna G, Winchester B, Day R, et al. Reduced heparan sulfate accumulation in enterocytes contributes to protein-losing enteropathy in a congenital disorder of glycosylation. Am J Pathol (2000) 157:1917-25. doi:10.1016/S0002-9440(10)64830-4.
163. Bode L, Salvestrini C, Park PW, Li JP, Esko JD, Yamaguchi Y, et al. Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. J Clin Invest (2008) 118:229-38. doi:10.1172/JCI32335.
164. Commane DM, Shortt CT, Silvi S, Cresci A, Hughes RM, Rowland IR. Effects of fermentation products of pro-and prebiotics on trans-epithelial electrical resistance in an in vitro model of the colon. Nutr Cancer (2005) 51:102-9. doi:10.1207/s15327914nc5101_14.
165. Qin HL, Shen TY, Gao ZG, Fan XB, Hang XM, Jiang YQ, et al. Effect of Lactobacillus on the gut microflora and barrier function of the rats with abdominal infection. World J Gastroenterol (2005) 11:2591-6.
166. Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, Schmidt MA. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol (2007) 9:804-16. doi:10.1111/j.1462-5822.2006.00836.x.
167. Mennigen R, Nolte K, Rijcken E, Utech M, Loeffler B, Senninger N, et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol (2009) 296:G1140-9. doi:10.1152/ajpgi.90534.2008.
168. Corridoni D, Pastorelli L, Mattioli B, Locovei S, Ishikawa D, Arseneau KO, et al. Probiotic bacteria regulate intestinal epithelial permeability in experimental ileitis by a TNF-dependent mechanism. PLoS One (2012) 7:e42067. doi:10.1371/journal.pone.0042067.
169. Pagnini C, Saeed R, Bamias G, Arseneau KO, Pizarro TT, Cominelli F. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc Natl Acad Sci U S A (2010) 107:454-9. doi:10.1073/pnas.0910307107.
170. Podolsky DK, Fournier DA. Alterations in mucosal content of colonic glycoconjugates in inflammatory bowel disease defined by monoclonal antibodies. Gastroenterology (1988) 95:379-87.
171. Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs (2005) 65:2253-86. doi:10.2165/00003495-200565160-00002.
172. Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol (2002) 97:2000-4. doi:10.1111/j.1572-0241.2002.05914.x.
173. Suenaert P, Bulteel V, Vermeire S, Noman M, Van Assche G, Rutgeerts P. Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependent. Inflamm Bowel Dis (2005) 11:667-73. doi:10.1097/01.MIB.0000168371.87283.4b.
174. Zeissig S, Bojarski C, Buergel N, Mankertz J, Zeitz M, Fromm M, et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut (2004) 53:1295-302. doi:10.1136/gut.2003.036632.
175. Marini M, Bamias G, Rivera-Nieves J, Moskaluk CA, Hoang SB, Ross WG, et al. TNF-alpha neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proc Natl Acad Sci U S A (2003) 100:8366-71. doi:10.1073/pnas.1432897100.
176. Mirpuri J, Brazil JC, Berardinelli AJ, Nasr TR, Cooper K, Schnoor M, et al. Commensal Escherichia coli reduces epithelial apoptosis through IFN-alphaA-mediated induction of guanylate binding protein-1 in human and murine models of developing intestine. J Immunol (2010) 184:7186-95. doi:10.4049/jimmunol.0903116.
177. Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med (2003) 349:350-7. doi:10.1056/NEJMoa013136.
178. Mashimo H, Wu DC, Podolsky DK, Fishman MC. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science (1996) 274:262-5. doi:10.1126/science.274.5285.262.
179. Mahmood A, Melley L, Fitzgerald AJ, Ghosh S, Playford RJ. Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis. Aliment Pharmacol Ther (2005) 21:1357-64. doi:10.1111/j.1365-2036.2005.02436.x.
180. Bock J, Liebisch G, Schweimer J, Schmitz G, Rogler G. Exogenous sphingomyelinase causes impaired intestinal epithelial barrier function. World J Gastroenterol (2007) 13:5217-25.
181. Gulbins E, Kolesnick R. Raft ceramide in molecular medicine. Oncogene (2003) 22:7070-7. doi:10.1038/sj.onc.1207146.
182. Megha S, London E. Ceramide selectively displaces cholesterol from ordered lipid domains (rafts): implications for lipid raft structure and function. J Biol Chem (2004) 279:9997-10004.
183. Rosella O, Sinclair A, Gibson PR. Polyunsaturated fatty acids reduce non-receptor-mediated transcellular permeation of protein across a model of intestinal epithelium in vitro. J Gastroenterol Hepatol (2000) 15:626-31. doi:10.1046/j.1440-1746.2000.02215.x.
184. Teitelbaum JE, Allan Walker W. Review: the role of omega 3 fatty acids in intestinal inflammation. J Nutr Biochem (2001) 12:21-32. doi:10.1016/S0955-2863(00)00141-8.
185. Usami M, Komurasaki T, Hanada A, Kinoshita K, Ohata A. Effect of gamma-linolenic acid or docosahexaenoic acid on tight junction permeability in intestinal monolayer cells and their mechanism by protein kinase C activation and/or eicosanoid formation. Nutrition (2003) 19:150-6. doi:10.1016/S0899-9007(02)00927-9.
186. Aslan A, Triadafilopoulos G. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol (1992) 87:432-7.
187. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med (1996) 334:1557-60. doi:10.1056/NEJM199606133342401.
188. Lorenz-Meyer H, Bauer P, Nicolay C, Schulz B, Purrmann J, Fleig WE, et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group). Scand J Gastroenterol (1996) 31:778-85. doi:10.3109/00365529609010352.
189. MacLean CH, Mojica WA, Newberry SJ, Pencharz J, Garland RH, Tu W, et al. Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease. Am J Clin Nutr (2005) 82:611-9.
190. Stremmel W, Merle U, Zahn A, Autschbach F, Hinz U, Ehehalt R. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut (2005) 54:966-71. doi:10.1136/gut.2004.052316.
191. Stremmel W, Ehehalt R, Autschbach F, Karner M. Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Ann Intern Med (2007) 147:603-10. doi:10.7326/0003-4819-147-9-200711060-00004.
192. Ehehalt R, Wagenblast J, Erben G, Lehmann WD, Hinz U, Merle U, et al. Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospray-tandem mass spectrometry. Scand J Gastroenterol (2004) 39:737-42. doi:10.1080/00365520410006233.
193. Tai EK, Wong HP, Lam EK, Wu WK, Yu L, Koo MW, et al. Cathelicidin stimulates colonic mucus synthesis by up-regulating MUC1 and MUC2 expression through a mitogen-activated protein kinase pathway. J Cell Biochem (2008) 104:251-8. doi:10.1002/jcb.21615.
194. Finnie IA, Dwarakanath AD, Taylor BA, Rhodes JM. Colonic mucin synthesis is increased by sodium butyrate. Gut (1995) 36:93-9. doi:10.1136/gut.36.1.93.
195. Hatayama H, Iwashita J, Kuwajima A, Abe T. The short chain fatty acid, butyrate, stimulates MUC2 mucin production in the human colon cancer cell line, LS174T. Biochem Biophys Res Commun (2007) 356:599-603. doi:10.1016/j.bbrc.2007.03.025.
196. Barcelo A, Claustre J, Moro F, Chayvialle JA, Cuber JC, Plaisancie P. Mucin secretion is modulated by luminal factors in the isolated vascularly perfused rat colon. Gut (2000) 46:218-24. doi:10.1136/gut.46.2.218.
197. Mariadason JM, Barkla DH, Gibson PR. Effect of short-chain fatty acids on paracellular permeability in Caco-2 intestinal epithelium model. Am J Physiol (1997) 272:G705-12.
198. Peng L, He Z, Chen W, Holzman IR, Lin J. Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res (2007) 61:37-41. doi:10.1203/01.pdr.0000250014.92242.f3.
199. Mariadason JM, Kilias D, Catto-Smith A, Gibson PR. Effect of butyrate on paracellular permeability in rat distal colonic mucosa ex vivo. J Gastroenterol Hepatol (1999) 14:873-9. doi:10.1046/j.1440-1746.1999.01972.x.
200. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther (2008) 27:104-19. doi:10.1111/j.1365-2036.2007.03562.x.
201. Steinhart AH, Hiruki T, Brzezinski A, Baker JP. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther (1996) 10:729-36. doi:10.1046/j.1365-2036.1996.d01-509.x.
202. Vernia P, Annese V, Bresci G, D'Albasio G, D'Inca R, Giaccari S, et al. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest (2003) 33:244-8. doi:10.1046/j.1365-2362.2003.01130.x.